ClinicalTrials.gg
CompletedNCT03965858Updated Apr 28, 2020

Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Depression

A Phase 2 interventional study of Esketamine DPI - low dose and Esketamine DPI - medium dose in Major Depressive Disorder, sponsored by Celon Pharma SA. Completed at 12 sites in Poland. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-04-28.

Sponsored by Celon Pharma SA · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 86 studies in Depressive Disorder, Major with a site in Poland — 15 open to participants now, 17 under way, 10 of them phase 3. Depressive Disorder, Major · Poland.

Enrollment
74th of 82
88 · median 464
Started
2019
with 6 others
Phase 2
20 of 86
4 open now
Registered
44th of 86
by date

Among the 86 studies in Depressive Disorder, Major with a site in Poland, this one is the 74th largest by enrollment of the 82 interventional ones that give a count, is one of 7 that started in 2019, is one of 20 in phase 2, and was the 44th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

15 of the 86 studies in Depressive Disorder, Major with a site in Poland are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies in Depressive Disorder, Major with a site in Poland, or all of them as a file.
02

Study summary

The purpose of the study is to determine the efficacy, safety and pharmacokinetics of inhaled Esketamine in participants with treatment-resistant depression (TRD) in the course of Major Depressive Disorder (MDD). The study is to determine the efficacy and dose response of three Esketamine doses, compared with placebo.

Read the detailed description

This is a randomized, multiple dose, placebo-controlled, double-blind, multicentre study of Esketamine DPI, inhalation powder delivered via dry powder inhaler (DPI) in participants with TRD in the course of MDD. There are 3 study phases: Screening phase, a two weeks double-blind treatment phase and a 6-week follow-up phase. Participants are to be randomized in 1:1:1:1 ratio to receive placebo or one of the three doses of Esketamine DPI. Participants from each group will receive different dosing sequences, consider as a single dose, corresponding to low, medium, high Esketamine dose or placebo. Participants will undergo one cycle of treatment consisting of four doses of Esketamine DPI or placebo over 14-day period. Participants safety will be monitored throughout the study.

03

Conditions studied

  • Major Depressive Disorder
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Gender: female or male,
  2. Age: 18 - 65 years old, inclusive, on the day of Screening,
  3. Participant must meet , fifth edition (DSM-5) diagnostic criteria for major depressive disorder, without psychotic features, confirmed by the Mini International Neuropsychiatric Interview (MINI),
  4. Participant must have in Montgomery-Asberg Depression Rating Scale (MADRS) total score of >= 25 at Screening and predose on Day 1,
  5. Participant is treatment resistant, defined as having an inadequate response to at least 2 antidepressants administered for the sufficient duration and dose, both in the current episode of depression,
  6. Participant must be on stable monotherapy with antidepressant drug (listed in the protocol) remain non-responsive to it and continue on non- antidepressant therapy from Screening to at least the duration of the double-blind treatment phase,
  7. Participant agrees to be hospitalized voluntarily for a period of 12 h before first administration and until the Day 6 of treatment phase. Hospitalization from Day 6 up to the end of treatment phase on Day 14 is up to Investigator discretion, with exception of mandatory hospitalization from 12 h before each administration until 24 h post each administration and from evening on Day 13 until the end of examinations on Day 14,
  8. Participant must be medically stable on the basis of clinical laboratory tests, physical examination, vital signs, 12-lead ,
  9. Participant agrees to blood sample collection for DNA analysis,
  10. Participant of willing to use acceptable forms of .

Exclusion criteria

Exclusion Criteria:

  1. Participant has a current diagnosis, according to MINI, of any other than MDD disorder,
  2. Participant has suicidal ideation in MADRS 'suicidal thoughts' subscale score greater or equal to 2 and/or in C-SSRS score greater or equal to 4 at Screening and/or has a history of suicidal thoughts within 6 months prior to Screening and/or history of suicidal attempt within 1 year prior to Screening,
  3. Participant has a history or current signs and symptoms of (COPD), asthma, liver or renal insufficiency, significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, hematologic, neurologic, rheumatologic or metabolic disturbances that are uncontrolled with medication change during last three months before Screening and/or that could influence the present general health condition at the Investigator's discretion,
  4. Participant has uncontrolled hypertension,
  5. Upper respiratory tract and/or chest infection and/or inflammation within 2 weeks preceding the first administration and during the treatment phase,
  6. Participant took part in other clinical trial within 90 days preceding the Screening,
  7. Known allergy or , intolerance or to Esketamine/ketamine or its derivatives and/or to any study product ,
  8. Blood drawn within 30 days prior to inclusion to the study,
  9. History of drug, alcohol, chemical, sedatives or sleeping medications abuse or dependence (except nicotine or caffeine) within 2 years prior to Screening,
  10. Lifetime abuse or dependence on ketamine or phencyclidine,
  11. Positive results from pregnancy test for female participants,
  12. Lactation in female participants,
  13. Positive drug screen (except benzodiazepines evaluation during follow-up) or alcohol breath test.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
88 participants (actual)

Study arms

  • Experimental
    Esketamine low dose

    Participants are to receive four doses of Esketamine DPI administered over 14-day period (on Day 1, 4, 8 and 11).

    Drug: Esketamine DPI - low dose

  • Experimental
    Esketamine medium dose

    Participants are to receive four doses of Esketamine DPI administered over 14-day period (on Day 1, 4, 8 and 11).

    Drug: Esketamine DPI - medium dose

  • Experimental
    Esketamine high dose

    Participants are to receive four doses of Esketamine DPI administered over 14-day period (on Day 1, 4, 8 and 11).

    Drug: Esketamine DPI - high dose

  • Placebo comparator
    Placebo

    Participants are to receive four doses of Placebo DPI administered over 14-day period (on Day 1, 4, 8 and 11).

    Drug: Placebo DPI

Interventions

  • DrugEsketamine DPI - low dose

    Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to low Esketamine dose.

  • DrugEsketamine DPI - medium dose

    Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to medium Esketamine dose.

  • DrugEsketamine DPI - high dose

    Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to high Esketamine dose.

  • DrugPlacebo DPI

    Placebo DPI is to be administered via dry powder inhaler.

06

What researchers measure

Primary outcomes

  1. Change from baseline in Montgomery-Asberg Depression Rating Scale (MADRS) total score at Day 14

    The MADRS is a clinician-rated scale designed to measure depression severity and detect changes due to antidepressant treatment. The test consists of 10 items, each scored from 0 (symptoms not present or normal) to 6 (severe or continuous presence of the symptoms). Total score is 60. The higher MADRS total score, the more severe depression.

    Time frame: Day 1 and Day 14

Secondary outcomes

  1. Change from baseline in MADRS total score at each other than Day 14 timepoint

    The MADRS is a clinician-rated scale designed to measure depression severity and detect changes due to antidepressant treatment. The test consists of 10 items, each scored from 0 (symptoms not present or normal) to 6 (severe or continuous presence of the symptoms). Total score is 60. The higher MADRS total score, the more severe depression.

    Time frame: Day 1, 2, 4, 5, 8, 9, 11, 12 and week 3, 4, 5, 6, 7 and 8

  2. Number of participants with clinical response (>= 50% decrease in MADRS baseline score)

    Clinical response is to be defined as greater than or equal to 50 % decrease in MADRS baseline score at Day 14 and every other timepoint.

    Time frame: Day 1, 2, 4, 5, 8, 9, 11, 12, 14 and up to 6 weeks after the treatment phase

  3. Onset of clinical response that was sustained through the end of the 2-week, double-blind, treatment phase

    Time frame: Day 1, 2, 4, 5, 8, 9, 11, 12, 14

  4. Change from baseline in depression severity, measured by Hamilton Depression Rating Scale (HDRS) at every timepoint

    HDRS is a questionnaire used to rate the severity of depression by probing mood, feelings of guilt, suicide ideation, insomnia, agitation or retardation, anxiety, weight loss and somatic symptoms. HDRS consists of 17 questions with maximum 4-points scale. The higher HDRS total score, the more severe depression.

    Time frame: Day 1, 2, 4, 5, 8, 9, 11, 12, 14 and week 3, 4, 5, 6, 7 and 8

  5. Number of participants with clinical remission (MADRS total score <= 10)

    Clinical remission, defined as MADRS total score less than or equal to 10.

    Time frame: Day 1, 2, 4, 5, 8, 9, 11, 12, 14 and up to 6 weeks after the treatment phase

  6. Time to relapse

    Relapse assessed for responders and remitters and defined when MADRS total score in 2 consecutive assessments after Day 14 exceeds 50% MADRS baseline total score value.

    Time frame: Day 14 and week 3, 4, 5, 6, 7 and 8

  7. Change from baseline in Clinical Global Impression - Severity (CGI-S) score at Day 14 and every other timepoint

    CGI-S scale is a physician-rated scale that is designed to rate the severity of the patient's illness at the time of assessment. It is a 7-point assessment where 1 = normal (not at all ill) and 7 = among the most extremely ill patients.

    Time frame: Day 1, 2, 4, 5, 8, 9, 11, 12, 14 and week 3, 4, 5, 6, 7 and 8

  8. Change from baseline in Columbia Suicide Severity Rating Scale (C-SSRS) at Day 14 and every other timepoint

    C-SSRS is a suicide ideation rating scale created by researchers at Columbia University.

    Time frame: Day 1, 14 and week 5, 8

  9. Change from baseline in the Clinician Administered Dissociative States Scale (CADSS) at each day of administration

    CADSS is a scale designed to assess dissociative symptoms. CADSS consists of 23 questions with 4-points scale, where 1=normal (not at all) and 4=Extremely. The higher CADSS total score, the more severe symptoms.

    Time frame: up to 24 hours following the start of each administration

  10. Change from baseline in the Brief Psychiatric Rating Scale (BPRS) at each day of administration

    BPRS is a scale designed to rate psychotomimetic effects. BPRS consists of 18 questions with 7-points scale, from 1 (not present) to 7 (extremaly severe). The higher BPRS total score, the more severe effects.

    Time frame: up to 24 hours following the start of each administration

  11. Potential withdrawal symptoms after Esketamine treatment, as measured by the 20-item Physician Withdrawal Checklist (PWC-20)

    PWC-20 is a method to assess discontinuation symptoms.

    Time frame: Day 0, week 3, 4 and 5

  12. Potential Esketamine effect on cognition as measured by Montreal Cognitive Assessment (MoCA)

    MoCA is a screening assessment for detecting cognitive impairment.

    Time frame: Day 0, week 4 and 8

  13. Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: up to 8 weeks

  14. Esketamine AUC0-24h - area under the plasma concentration - time curve from time 0 to 24 h

    Time frame: up to 24 hours following the start of first and fourth administration

  15. Esketamine Cmax - maximum plasma concentration

    Time frame: up to 24 hours following the start of first and fourth administration

  16. Esketamine AUC0-inf - area under the plasma concentration - time curve from time 0 to infinity

    Time frame: up to 24 hours following the start of first and fourth administration

  17. Esketamine Kel - terminal elimination rate constant

    Time frame: up to 24 hours following the start of first and fourth administration

  18. Esketamine t1/2 - plasma elimination half-life

    Time frame: up to 24 hours following the start of first and fourth administration

  19. Esketamine Tmax - time to reach maximum concentration in plasma

    Time frame: up to 24 hours following the start of first and fourth administration

  20. Esnorketamine AUC0-24h - area under the plasma concentration - time curve from time 0 to 24 h

    Time frame: up to 24 hours following the start of first and fourth administration

  21. Esnorketamine Cmax - maximum plasma concentration

    Time frame: up to 24 hours following the start of first and fourth administration

  22. Esnorketamine Tmax - time to reach maximum concentration in plasma

    Time frame: up to 24 hours following the start of first and fourth administration

  23. Changes between predose and postdose values for each administration in hematology and biochemistry

    Time frame: up to 6 weeks

  24. Changes between predose and postdose values for each administration in vital signs (heart rate, blood pressure, respiratory rate) and urinalysis

    Time frame: up to 8 weeks

  25. Changes between predose and postdose values for each administration in SpO2 (blood oxygen saturation)

    Time frame: up to 2 hours following the start of each administration

07

Study locations

12 sites
  • Wojewodzki Szpital im. Jana Pawła II
    Belchatow, 97-400, Poland
  • Wojewodzki Szpital dla Nerwowo i Psychicznie Chorych
    Boleslawiec, 59-700, Poland
  • Samodzielny Publiczny Psychiatryczny Zaklad Opieki Zdrowotnej
    Choroszcz, 16-070, Poland
  • Szpital Miejski
    Elblag, 82-300, Poland
  • Uniwersyteckie Centrum Kliniczne
    Gdansk, 80-952, Poland
  • Gornoslaskie Centrum Medyczne
    Katowice, 40-635, Poland
  • Specjalistyczny Psychiatryczny Zespol Opieki Zdrowotnej
    Lodz, 91-229, Poland
  • Pabianickie Centrum Medyczne
    Pabianice, 95-200, Poland
  • Mazowieckie Specalistyczne Centrum Zdrowia
    Pruszkow, 05-802, Poland
  • Wojewodzki Szpital dla Nerwowo i Psychicznie Chorych
    Swiecie, 86-100, Poland
  • Mazowiecki Szpital i Centrum Diagnostyczne Allenort
    Warsaw, 03-185, Poland
  • Uniwersytecki Szpital Kliniczny
    Wroclaw, 50-556, Poland
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2019 to primary completion in Mar 2020, 12 months.

Of 96 industry-sponsored phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 23. This study's 12 months is below that.

Counting every sponsor, half of 195 studies reached it within 22 months; a quarter within 14 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2019
First posted
May 29, 2019
StartActual
Feb 25, 2019
Primary completionActual
Mar 15, 2020
CompletionActual
Apr 24, 2020
Last update
Apr 28, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03965858
Lead sponsor
Celon Pharma SA
Collaborators
National Center for Research and Development, Poland
Responsible party
Sponsor
First posted
May 29, 2019
Start date
Feb 25, 2019
Primary completion
Mar 15, 2020
Completion
Apr 24, 2020
Last update
Apr 28, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion